Profilo
Irene Schiller is the founder and Chief Medical Officer at Malcisbo AG, which is founded in 2010.
She is currently a Professor at the University of Bern.
Dr. Schiller was previously a Manager-Marketing & Sales at Prionics AG.
She earned a doctorate degree from the University of Zurich.
Posizioni attive di Irene Schiller
| Società | Posizione | Inizio |
|---|---|---|
Malcisbo AG
 Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Fondatore | 01/05/2010 |
| University of Bern | Corporate Officer/Principal | - |
Precedenti posizioni note di Irene Schiller
| Società | Posizione | Fine |
|---|---|---|
Prionics AG
 Prionics AG Medical SpecialtiesHealth Technology Prionics AG engages in the research in as well as the development, production, and distribution of diagnostic solutions for farm animal diseases. It focuses on diseases that can be transmitted from animals to human beings such as mad cow's disease and other prion diseases. The company was founded by Bruno Oesch and Markus Moser on February 27, 1997 and is headquartered in Schlieren, Switzerland. | Vendite & Marketing | - |
Formazione di Irene Schiller
| University of Zurich | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |
Prionics AG
Prionics AG Medical SpecialtiesHealth Technology Prionics AG engages in the research in as well as the development, production, and distribution of diagnostic solutions for farm animal diseases. It focuses on diseases that can be transmitted from animals to human beings such as mad cow's disease and other prion diseases. The company was founded by Bruno Oesch and Markus Moser on February 27, 1997 and is headquartered in Schlieren, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Irene Schiller